Samson Clinical

Samson Clinical has developed a patented low-dose sublingual minoxidil tablet for the treatment of androgenetic alopecia. The company’s approach aims to provide an effective, safe, and easy-to-use therapy for hair loss. Early clinical results have shown promise in efficacy and safety profiles compared to traditional topical or oral formulations[1]. The company was founded by Professor Rodney Sinclair, a leading dermatologist and academic with extensive research credentials in hair biology and androgenetic alopecia[1]. As of June 2025, the company remains unlisted and actively seeks partnerships with pharmaceutical companies, distributors, and licensees to advance commercialization[1].